Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.33 |
| ▸ | MAOB | P27338 | 6/20 | 0.33 |
| ▸ | AOC2 | O75106 | 5/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209606 | 0.81 | MAOB (0.41) | MAOAMAOBAOC2DAOHPGD | |
| SCHEMBL18493846 | 0.80 | HRH3 (0.36) | MAOAMAOBAOC2DAOHRH3 | |
| SCHEMBL27651808 | 0.79 | MAOB (0.41) | MAOAMAOBAOC2DAOHPGD | |
| SCHEMBL28992030 | 0.76 | ACHE (0.36) | MAOB | |
| SCHEMBL449445 | 0.75 | MAOA (0.37) | MAOAMAOBAOC2DAOHPGD | |
| SCHEMBL28766178 | 0.73 | L3MBTL1 (0.35) | — | |
| SCHEMBL5572317 | 0.72 | MAOA (0.38) | MAOAMAOBAOC2DAOHPGD | |
| SCHEMBL2449240 | 0.71 | MAOA (0.37) | MAOAMAOBAOC2DAOHPGD | |
| SCHEMBL11381215 | 0.71 | MAOA (0.37) | MAOAMAOBAOC2CHRM2CHRM4 | |
| SCHEMBL1890900 | 0.71 | MAOA (0.37) | MAOAMAOBAOC2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834010-B2 | Modulators of peripheral 5-HT receptors | SERODUS AS (NO) | 2010-11-16 | — | — | US | disclosed |
| EP-2064177-A2 | PROTEASE INHIBITORS | Ambrilia Biopharma Inc. (CA) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008078200-A2 | PROTEASE INHIBITORS | AMBRILIA BIOPHARMA INC. (CA) | 2008-07-03 | — | — | WO | disclosed |
| US-7323473-B2 | Administering (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine; serotonin receptor antagonists (5HT/5HT2C) for treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323487-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20070254874-A1 | Modulators of Preripheral 5-Ht Receptors | BIO-MEDISINSK INNOVASJON (NO) | 2007-11-01 | — | — | US | disclosed |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-03 | — | — | US | disclosed |
| EP-1112270-B1 | DIHYDROBENZODIOXINE CARBOXAMIDE AND KETONE DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1701951-A2 | MODULATORS OF PERIPHERAL 5-HT RECEPTORS | Bio-Medisinsk Innovasjon AS (NO) | 2006-09-20 | — | — | EP | disclosed |
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005061483-A2 | MODULATORS OF PERIPHERAL 5-HT RECEPTORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2005-07-07 | — | — | WO | disclosed |
| US-6914160-B1 | Oxytocin inhibitors | PFIZER INC (US) | 2005-07-05 | — | — | US | disclosed |
| EP-1537085-A1 | OXYTOCIN INHIBITORS | Pfizer Limited (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004020414-A1 | OXYTOCIN INHIBITORS | PFIZER LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
| EP-1112270-A1 | DIHYDROBENZODIOXINE CARBOXAMIDE AND KETONE DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-04 | — | — | EP | disclosed |
| US-6172062-B1 | ANTISEROTONIN AGENTS; GASTROINTESTINAL DISORDERS; CARDIOVASCULAR DISORDERS; NERVOUS SYSTEM DISORDERS | SYNTEX (USA) LLC | 2001-01-09 | — | — | US | disclosed |
| WO-2000015636-A1 | DIHYDROBENZODIOXINE CARBOXAMIDE AND KETONE DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | MAOA 4355/4885MAOB 4541/4885AOC2 4455/4885 |
| US-20070254874-A1 | Modulators of Preripheral 5-Ht Receptors | HTR4, HTR5A, HTR6 | MAOA 347/4885MAOB 373/4885AOC2 3833/4885 |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | HTR2C, HTR2A, HTR5A | MAOA 529/4885MAOB 406/4885AOC2 1142/4885 |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | MAOA 490/4885MAOB 369/4885AOC2 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.